We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Rexahn Pharmaceuticals Inc | NASDAQ:REXN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.81 | 1.75 | 1.83 | 0 | 01:00:00 |
Delaware
|
001-34079
|
11-3516358
|
||
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
||
37000 Grand River Avenue, Suite 120
Farmington Hills,
MI
|
48335
|
|||
(Address of principal executive offices)
|
(Zip Code)
|
N/A
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.0001 par value
|
OCUP
|
|
Emerging growth company ☐
|
|
Item 7.01 |
Regulation FD Disclosure.
|
Item 8.01 |
Other Events.
|
Item 9.01 |
Financial Statements and Exhibits.
|
Exhibit
Number
|
Exhibit Description
|
|
Investor Presentation Materials, dated March 29, 2022
|
||
Press Release, dated March 29, 2022
|
||
104
|
Cover Page Interactive Data File (embedded within Inline XBRL document).
|
OCUPHIRE PHARMA, INC.
|
||
By:
|
/s/ Mina Sooch
|
|
Mina Sooch
|
||
Chief Executive Officer
|
||
Date: March 29, 2022
|
1 Year Rexahn Pharmaceuticals Chart |
1 Month Rexahn Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions